New ISHLT Document on Strategies to Prevent and Manage Hemocompatibility Related Adverse Events in MCS Patients
A new ISHLT Document, An ISHLT Consensus Statement on Strategies to Prevent and Manage Hemocompatibility Related Adverse Events in Patients with a Durable, Continuous-Flow Ventricular Assist Device, has been published in JHLT and is available to read online! Led by Ian Hollis,
this document provides current best evidence and practices in the prevention and management of hemocompatibility-related adverse events (HRAEs).
Despite significant improvements in the delivery of care for patients with durable, continuous-flow left ventricular assist devices (CF-LVAD), HRAEs are still a concern and contribute to significant morbility and mortality when they occur. This ISHLT Consensus Statement is intended to assist clinicians caring for patients with a
CF-LVAD provide the best care possible with respect to prevention and
management of HRAEs through optimal management of oral anticoagulant and antiplatelet medica- tions, parenteral anticoagulant medications, management of patients at high risk for HRAEs and those experiencing thrombotic or bleeding events, and device management outside of antithrombotic medications.
Visit the Standards & Guidelines page for details, top takeaways, and links to read or download the document.